Vaccination against COVID-19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders

Affiliations

• ¹ Coagulation Product Safety, Supply and Access Committee, World Federation of Hemophilia, Montreal, Quebec, Canada.
• ² Shabrawishi Hospital Blood Transfusion & Hemophilia Treatment Center, Giza, Egypt.
• ³ The Royal London Hospital Haemophilia Centre, Barts Health NHS Trust, London, UK.
• ⁴ Centre for Immunobiology, Blizard Institute, Barts and The London School of Medicine and Dentistry, QMUL, London, UK.
• ⁵ Hemostasis and Thrombosis Unit, Division of Hematology, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium.
• ⁶ Medical Advisory Group, European Haemophilia Consortium, Brussels, Belgium.
• ⁷ European Haemophilia Consortium, Brussels, Belgium.
• ⁸ Irish Haemophilia Society, Dublin, Ireland.
• ⁹ Trinity College, Dublin, Ireland.
• ¹⁰ Canadian Hemophilia Society, Montreal, Canada.
• ¹¹ Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy.
• ¹² Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy.
• ¹³ Medical and Scientific Advisory Council, National Hemophilia Foundation, New York, NY, USA.
• ¹⁴ Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, MI, USA.
• ¹⁵ Association Française des Hémophiles, Paris, France.
• ¹⁶ German Haemophilia Society, Hamburg, Germany.
• ¹⁷ Institute for Policy Advancement Ltd, Washington, DC, USA.
• ¹⁸ McMaster University, Hamilton, Ontario, Canada.
• ¹⁹ Department of Haematology, Christian Medical College, Vellore, India.
• ²⁰ World Federation of Hemophilia, Montreal, Quebec, Canada.